 M-of-18 Ig is a promising new treatment for cancer. It is a chimeric Ig antibody that can target specific proteins on cancer cells, which may help to destroy them. In this clinical trial, it was found to be safe and well tolerated when administered to patients with various types of cancer. Additionally, some patients showed signs of tumor aggression after receiving the drug. This suggests that M-of-18 Ig may have potential as a novel therapeutic option for treating cancer. This article was authored by James Spicer, Bristol Bosser, Anna Montes, and others.